Jonas Jost B, Spandau Ulrich H, Schlichtenbrede Frank
Department of Ophthalmology, Faculty of Clinical Medicine Mannheim, Ruprecht-Karls University Heidelberg, Mannheim, Germany.
Ophthalmic Res. 2007;39(2):121-2. doi: 10.1159/000099248. Epub 2007 Feb 2.
It was the aim of this study to report on the intravitreal use of bevacizumab as antiproliferative agent in combination with filtering surgery.
The clinical interventional case series study included 2 patients (2 eyes) who underwent standard antiglaucomatous penetrating filtering surgery combined with an intravitreal application of 1.5 mg bevacizumab. The intraocular pressure was elevated due to an intravitreal triamcinolone injection as treatment of exudative age-related macular degeneration (patient No. 1) or due to neovascular glaucoma (patient No. 2) after an ischemic retinal branch vein occlusion.
At 4 and 12 weeks after surgery, intraocular pressure was reduced in both patients to 10 and 14 mm Hg with functioning filtering blebs.
Intravitreal bevacizumab may potentially be helpful as addition to antiglaucomatous filtering surgery, particularly in neovascular glaucoma.
本研究旨在报告玻璃体内使用贝伐单抗作为抗增殖剂联合滤过手术的情况。
临床干预性病例系列研究纳入了2例患者（2只眼），他们接受了标准的抗青光眼穿透性滤过手术，并玻璃体内注射1.5毫克贝伐单抗。患者1因玻璃体内注射曲安奈德治疗渗出性年龄相关性黄斑变性导致眼压升高，患者2因缺血性视网膜分支静脉阻塞后继发新生血管性青光眼导致眼压升高。
术后4周和12周时，两名患者的眼压均降至10至14毫米汞柱，滤过泡功能良好。
玻璃体内注射贝伐单抗作为抗青光眼滤过手术的辅助治疗可能有帮助，尤其是在新生血管性青光眼中。
Zotero 插件